<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446093</url>
  </required_header>
  <id_info>
    <org_study_id>PaTK02</org_study_id>
    <nct_id>NCT02446093</nct_id>
  </id_info>
  <brief_title>Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma</brief_title>
  <acronym>PaTK02</acronym>
  <official_title>Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advantagene, Inc. d.b.a. Candel Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Advantagene, Inc. d.b.a. Candel Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Gene Mediated Cytotoxic Immunotherapy (GMCI™) in
      combination with standard of care chemoradiation and surgery for borderline resectable and
      unresectable locally advanced pancreatic cancer in patients who have completed induction
      chemotherapy. GMCI kills tumor cells and creates an immune stimulatory environment in the
      tumor. Killing tumor cells in an immune stimulatory environment induces the body's immune
      system to detect and destroy cancer cells. GMCI has shown synergy with radiation and surgery
      without added toxicity. The hypothesis is that GMCI added to standard of care chemoradiation
      and surgery after completion of induction chemotherapy will be safe and will improve the
      clinical outcome for patients with pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GMCI involves the injection of aglatimagene besadenovec (AdV-tk) into the tumor followed by
      oral valacyclovir pills to kill tumor cells and stimulate a cancer vaccine effect. The
      current protocol is designed to deliver multiple courses of GMCI in combination with standard
      of care chemoradiation and surgery to capitalize on the synergies with the different
      treatment modalities.

      This protocol includes two phases:

        -  Phase 1b - completed.

        -  The Phase 2 is a randomized study comparing a test group receiving GMCI added to
           chemoradiation and surgery to a control arm receiving chemoradiation followed by
           surgery. Participants will be randomized in a 1:1 ratio to GMCI plus standard of care or
           standard of care alone. Both arms receive standard of care treatment and evaluations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resection rate</measure>
    <time_frame>4 months</time_frame>
    <description>The percentage of patients receiving an R0 resection will be compared between the two arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety graded by CTC ver4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of adverse events will be compared between the two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of patients alive at 2 years will be compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The PFS curves will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GMCI + chemoadiation + surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemoradiation + surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GMCI</intervention_name>
    <description>Intratumoral cytotoxic immunotherapy using an adenoviral vector expressing HSV-tk followed by anti-herpetic prodrug valacyclovir</description>
    <arm_group_label>Test Arm</arm_group_label>
    <other_name>AdV-tk (aglatimagene besadenovec) + valacyclovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Standard of care chemotherapy given with radiation</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Test Arm</arm_group_label>
    <other_name>Standard of care radiation given with chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Pancreaticoduodenectomy (Whipple)</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Test Arm</arm_group_label>
    <other_name>Pancreatic cancer resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological diagnosis of pancreatic adenocarcinoma adequately treated with induction
             chemotherapy for at least 2 months such that they are a candidate for localized
             therapy with chemoradiation followed by surgery with or without major vascular
             resection.

          -  Patients must be deemed to be in adequate health to undergo major surgery
             (pancreaticoduodenectomy)

          -  Tumor accessible for injection that is classified as borderline-resectable or locally
             advanced but considered potentially resectable after central review by surgical
             investigators (based upon pre-induction chemotherapy imaging). Resection may include
             major vascular resection with reconstruction as needed.

          -  Age 18-76 years

          -  Performance status ECOG 0-1

          -  SGOT (AST)&lt;3x upper limit of normal

          -  Total bilirubin ≤2mg/dl

          -  Creatinine&lt;2mg/dl

          -  Calculated creatinine clearance &gt;30ml/m

          -  WBC&gt;3000/mm3

          -  Absolute neutrophil count (ANC)&gt;1500/mm3

          -  Platelets&gt;100,000/mm3

          -  Hemoglobin &gt; 9 g/dL.

          -  Patients must give study specific informed consent prior to enrollment

        Exclusion Criteria:

          -  Primary hepatic dysfunction including known cirrhosis or active hepatitis. Patients
             with biliary obstruction must be stented prior to initiating treatment.

          -  Evidence of clinically significant pancreatitis as determined by the investigator

          -  Evidence of significant ascites as determined by the investigator

          -  Patients on systemic corticosteroids (&gt;10 mg prednisone per day or equivalent) or
             other systemic immunosuppressive drugs

          -  Known to be HIV+

          -  Pregnant or breast-feeding. Female patients of childbearing age must have negative
             serum or urine pregnancy test within 1 week of beginning therapy.

          -  Other current malignancy (except squamous or basal cell skin cancers)

          -  Other serious co-morbid illness or compromised organ function

          -  Known sensitivity or allergic reactions to acyclovir or valacyclovir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lee Health/Regional Cancer Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina A Ward</last_name>
      <phone>239-343-9547</phone>
      <email>alina.ward@LeeHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Mark Bloomston, MD</last_name>
      <phone>(239) 333-0995</phone>
      <email>mark.bloomston@21co.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Bloomston, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamida Umar</last_name>
      <phone>614-685-6406</phone>
      <email>Hamida.Umar@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Dillhoff, MD</last_name>
      <phone>614-293-4583</phone>
      <email>Mary.Dillhoff@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Dilhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Uscanga, M.D</last_name>
      <phone>+52 (55)54870900</phone>
      <phone_ext>4401</phone_ext>
      <email>luis.uscangad@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreas cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>GMCI</keyword>
  <keyword>AdV-tk</keyword>
  <keyword>aglatimagene besadenovec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

